Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
DOSSIER-ID: HRB-SYNTH-INIT
TIMESTAMP: 2026-09-13 02:07:23 UTC
Strong Evidence
Withania somnifera (Ashwagandha) in HPA-Axis Regulation
Synthesized Audio Monograph
Chapter 1: Executive Summary & Key Findings
1. Executive Summary & Evidence Grounding
Meta-analyses of randomized double-blind placebo-controlled trials indicate statistically significant modulation of the hypothalamic-pituitary-adrenal (HPA) axis following administration of standardized root extract (KSM-66, Sensoril). Reductions in morning salivary cortisol correlate with improvements in validated psychometric stress assessments.
Certainty Rationale: Twelve independent randomized controlled trials (n=1,280) demonstrated consistent biomarker improvements with low risk of bias across primary outcomes.
Key Research Findings:
- Serum cortisol concentrations reduced by 22.4% to 27.9% compared to placebo over 60 days.
- Dose-dependent enhancement of self-reported sleep quality and sleep onset latency.
- GABA-mimetic receptor binding affinity demonstrated in both in vivo and ex vivo models.
2. Botanical Identity & Bioactive Compounds
Relevant Herbs:
Withania somnifera (L.) Dunal
Target Phytochemicals:
Withanolide A
Withaferin A
Withanone
3. Evidence Stratification Matrix
Human Clinical Research (In Vivo)
Primary evidence stems from 12 double-blind randomized trials with adult populations (300mg to 600mg standardized root extract daily). Consistent reductions in stress biomarkers (cortisol, DHEA-S) were observed with statistical significance (p < 0.001).
Preclinical & Animal Research
Murine rodent restraint-stress models confirm attenuation of adrenal hypertrophy and preservation of corticosterone circadian rhythmicity.
Mechanistic & Pharmacokinetic Pathways
Withanolides cross the blood-brain barrier and allosterically modulate GABA_A receptors while downregulating CRH (Corticotropin-Releasing Hormone) gene transcription in the paraventricular nucleus.
4. Safety, Toxicology & Drug Interactions
Safety Profile:
- Generally well tolerated up to 1,000mg/day for 12 weeks.
- Occasional mild gastrointestinal discomfort reported.
Herb-Drug Interactions:
- Synergistic sedation with Benzodiazepines and CNS depressants.
- Potential potentiation of thyroid hormone replacement therapies.
Population Considerations:
- Contraindicated during pregnancy (abortifacient concerns in traditional literature).
- Caution in autoimmune disorders due to immunostimulatory properties.
5. Methodological Limitations & Evidence Gaps
Study Limitations:
- Most clinical trials limited to 8 to 12 week durations; lack of longitudinal safety data beyond 6 months.
- Variation in withanolide content between commercial extracts (Sensoril 10% vs KSM-66 5%).
Critical Research Gaps:
- Comparative bioavailability between whole root powder versus standardized ethanolic extracts.
- Direct head-to-head clinical trials with first-line anxiolytics.
6. Peer-Reviewed Citations & Literature Grounding
- Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. 2012;34(3):255-262.
- Lopresti AL, Smith SJ, Malvi H, Kodgire R. An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract. Medicine (Baltimore). 2019;98(37):e17186.
Publication Range: 2012 – 2024